Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2490
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience ; volume:12 ; number:1 ; day:22 ; month:2 ; year:2012 ; pages:1-7 ; date:12.2012
BMC urology ; 12, Heft 1 (22.2.2012), 1-7, 12.2012

Creator
Nakano, Kazuhiko
Contributor
Ohta, Shigeyuki
Komatsu, Kenji
Kubo, Taro
Nukui, Akinori
Suzuki, Kazumi
Kurokawa, Shinsuke
Kobayashi, Minoru
Morita, Tatsuo
SpringerLink (Online service)

DOI
10.1186/1471-2490-12-3
URN
urn:nbn:de:1111-2016071624908
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:53 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Nakano, Kazuhiko
  • Ohta, Shigeyuki
  • Komatsu, Kenji
  • Kubo, Taro
  • Nukui, Akinori
  • Suzuki, Kazumi
  • Kurokawa, Shinsuke
  • Kobayashi, Minoru
  • Morita, Tatsuo
  • SpringerLink (Online service)

Other Objects (12)

JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance

JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance

Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer

Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

Targeting molecular resistance in castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Osteoclasts directly influence castration-resistant prostate cancer cells

Osteoclasts directly influence castration-resistant prostate cancer cells

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival

Effect of simvastatin on castration-resistant prostate cancer cells

Effect of simvastatin on castration-resistant prostate cancer cells

Ureter metastatic castration-resistant prostate cancer: a case report

Ureter metastatic castration-resistant prostate cancer: a case report

Related objects